Compare Inovio Pharmaceuticals Inc (INO) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Direxion Daily FTSE China Bull 3x Shares trades at $25.19 (market cap $560.32M). The key difference: Direxion Daily FTSE China Bull 3x Shares is far larger — about 5× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| INO | YINN | |
|---|---|---|
Market Cap | $112.19M | $560.32M |
Volume | 3,201,278 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.65 | $52.69 |
52-Week Low | $0.66 | $21.45 |
Typical Hold Time | 43 Days | 25 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
YINN is trading at $25.09, up 6.49% in the past 24 hours, though technical indicators signal a bearish trend with 17 sell signals versus 2 buy signals. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies and export controls, which may impact the underlying index exposure. Financial ratios remain unavailable for analysis.
The outlook is cautious due to bearish technicals and China-related macroeconomic risks. Opportunities exist if support holds and sentiment improves, but investors face volatility from regulatory developments and weak momentum. Risk management is essential given the conflicting signals between price action and technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
